Hanyu Pharmaceutical announced that the company recently received the HY3003 injection clinical trial license notice issued by the US FDA. The FDA has completed the safety review of the IND application and agreed that the company will conduct the first clinical trial according to the submitted plan. HY3003 is a novel GLP-1R/GIPR/GCGR triple receptor agonist deployed by the company. The approved injection is a weekly preparation that is injected subcutaneously once a week, and is intended for use in indications such as weight loss, type 2 diabetes, and metabolism-related steatohepatitis. The project will need to complete multiple phase clinical trials and be reviewed and approved by the FDA before it can be marketed. There is uncertainty about research and development.

Hanyu Pharmaceutical announced that the company recently received the HY3003 injection clinical trial license notice issued by the US FDA. The FDA has completed the safety review of the IND application and agreed that the company will conduct the first clinical trial according to the submitted plan. HY3003 is a novel GLP-1R/GIPR/GCGR triple receptor agonist deployed by the company. The approved injection is a weekly preparation that is injected subcutaneously once a week, and is intended for use in indications such as weight loss, type 2 diabetes, and metabolism-related steatohepatitis. The project will need to complete multiple phase clinical trials and be reviewed and approved by the FDA before it can be marketed. There is uncertainty about research and development.